Drug intelligence / Profile preview

HSV 2 Formulation 6

Development stage: Preclinical
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HSV 2 Formulation 6 is an investigational vaccine regimen developed by Sanofi Pasteur, a Sanofi Company, for the prevention and treatment of recurrent genital herpes caused by Herpes Simplex Virus type 2 (HSV-2). It is administered via the intramuscular route. Clinical trials are evaluating its safety profile and efficacy in reducing the frequency of HSV DNA detection in the genital area (shedding rate) and the proportion of participants free of HSV genital recurrence.

Beyond the preview

Go deeper on HSV 2 Formulation 6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSV 2 Formulation 6.

Explore the full profile